Although Iniparib has a poor track record of failure, PARP inhibitors have returned to the breast cancer arena after breaking through the ovarian cancer barrier, with Olaparib and Talazoparib succeeding in single-drug therapy for patients with advanced metastatic disease [2-3].
However, in breast...
Read more